Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

被引：0
|
作者：
A. Svedbom
P. Hadji
E. Hernlund
R. Thoren
E. McCloskey
R. Stad
B. Stollenwerk
机构：
[1] ICON,Centre for Metabolic Bone Diseases
[2] Frankfurt Center of Bone Disease,Centre for Integrated research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research
[3] Philips-University of Marburg,undefined
[4] University of Sheffield,undefined
[5] University of Sheffield,undefined
[6] Amgen Europe (GmbH),undefined
来源：
Osteoporosis International | 2019年 / 30卷
关键词：
Costs and costs analysis; Cost-benefit analysis; Cost-effectiveness; Osteoporosis; Osteoporotic fracture; Preventive medicine; Practice patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1745 / 1754
页数：9
相关论文
共 50 条
  • [41] Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX®
    Martin-Sanchez, Mario
    Comas, Merce
    Posso, Margarita
    Louro, Javier
    Domingo, Laia
    Tebe, Cristian
    Castells, Xavier
    Espallargues, Mireia
    CALCIFIED TISSUE INTERNATIONAL, 2019, 105 (03) : 263 - 270
  • [42] STATUS OF COMPASSIONATE USE PROGRAMMES (CUP) IN THE EU-5 (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM)
    De Cock, E.
    Kolochavina, M.
    VALUE IN HEALTH, 2019, 22 : S786 - S786
  • [43] Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in Spain and Germany
    Taylor, D. C.
    Pandya, A.
    Thompson, D.
    Chu, P.
    Graff, J.
    LaRosa, J. C.
    Grundy, S. M.
    Wenger, N. K.
    Shepherd, J.
    Drummond, M. F.
    VALUE IN HEALTH, 2006, 9 (06) : A345 - A345
  • [44] Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in spain and germany
    Taylor, D. C. A.
    Pandya, A.
    Thompson, D.
    Chu, P.
    Graff, J.
    LaRosa, J. C.
    Grundy, S. M.
    Shepherd, I.
    Wenger, N. K.
    Drummond, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 125 - 125
  • [45] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
    M. F. Botteman
    M. Meijboom
    I. Foley
    J. M. Stephens
    Y. M. Chen
    S. Kaura
    The European Journal of Health Economics, 2011, 12 : 575 - 588
  • [46] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom
    Botteman, M. F.
    Kaura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
    Botteman, M. F.
    Meijboom, M.
    Foley, I.
    Stephens, J. M.
    Chen, Y. M.
    Kaura, S.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (06): : 575 - 588
  • [48] The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain (vol 9, 22, 2019)
    Runken, M. Chris
    Caraceni, Paolo
    Fernandez, Javier
    Zipprich, Alexander
    Carlton, Rashad
    Bunke, Martin
    HEALTH ECONOMICS REVIEW, 2020, 10 (01)
  • [49] COMPARATIVE ANALYSIS OF PRICING AND REIMBURSEMENT POLICIES AND METHODS: FOR PREVENTION AND CONTROL OF DISEASES CAUSED BY HIV INFECTIONS IN THE UNITED KINGDOM, GERMANY, FRANCE, ITALY, SPAIN, AND BULGARIA
    Dimitrova, M.
    Dimitrova, M.
    VALUE IN HEALTH, 2022, 25 (01) : S155 - S155
  • [50] VALUE OF LIFE AND COST OF PRE-MATURE DEATHS WITH THE PERSPECTIVE OF PRODUCTIVITY AS NET TAX REVENUE: A COMPARISON IN FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM
    Tuna, E.
    Yenilmez, F. B.
    Atikeler, K.
    Kockaya, G.
    Tatar, M.
    VALUE IN HEALTH, 2014, 17 (07) : A424 - A424
12345